What Is 17α-Dihydroequilin sodium sulfate

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 14, 2026

Quick Answer: 17α-Dihydroequilin sodium sulfate is a synthetic estrogen used in hormone replacement therapy, approved by the FDA in 2003 as part of the drug combination known as Tri-Estrogen. It is derived from pregnant mare urine and functions to balance hormone levels in menopausal women.

Key Facts

FDA approved the drug containing 17α-Dihydroequilin sodium sulfate in 2003
It is a component of Tri-Estrogen, a synthetic estrogen blend
Derived from conjugated estrogens found in pregnant mare urine
Used primarily in menopausal hormone replacement therapy
Acts by mimicking natural estrogen in the human endocrine system

Overview

17α-Dihydroequilin sodium sulfate is a synthetic estrogen compound used primarily in hormone replacement therapy (HRT) for menopausal women. It is one of several active ingredients in a formulation designed to alleviate symptoms such as hot flashes, vaginal dryness, and bone density loss.

This compound is a sodium salt form of 17α-dihydroequilin, a steroid structurally similar to human estrogens. It is derived from conjugated estrogens isolated from the urine of pregnant mares, a source commonly used in pharmaceutical estrogens.

17α-Dihydroequilin sodium sulfate is a water-soluble form of the steroid, enabling efficient absorption when administered orally in tablet form.
The compound was first approved by the FDA in 2003 as part of a multi-component estrogen therapy product known as Tri-Estrogen.
It is synthesized from pregnant mare urine, a well-established source for conjugated estrogens used in treatments like Premarin.
Unlike natural human estrogens, this compound is semi-synthetic, modified to improve stability and bioavailability in the body.
It is primarily prescribed to women experiencing moderate to severe menopausal symptoms, including night sweats and mood swings.

How It Works

17α-Dihydroequilin sodium sulfate functions by mimicking the biological activity of natural estrogens in the body. It binds to estrogen receptors in various tissues, including bone, brain, and reproductive organs, helping to regulate hormonal balance.

Mechanism of Action: The compound binds to estrogen receptors alpha and beta in target tissues, activating gene transcription that regulates cell function and hormone response.
Metabolism: Once ingested, it is metabolized in the liver into active and inactive metabolites, with a half-life of approximately 12–18 hours.
Bioavailability: Oral administration results in bioavailability of about 75%, enhanced by its sodium sulfate formulation for improved solubility.
Target Tissues: It exerts effects on bone density, central nervous system, and vaginal epithelium, reducing osteoporosis risk and urogenital atrophy.
Dosage: Typical doses range from 0.3 mg to 1.25 mg daily, depending on symptom severity and patient response.
Drug Interactions: It may interact with CYP3A4-inducing drugs like rifampin, potentially reducing its effectiveness due to accelerated metabolism.

Key Comparison

Compound	Source	Approval Year	Primary Use	Half-Life (hrs)
17α-Dihydroequilin sodium sulfate	Pregnant mare urine	2003	Hormone replacement therapy	12–18
Estradiol	Synthetic or bioidentical	1940s	Menopause, hypogonadism	13–17
Premarin (conjugated estrogens)	Pregnant mare urine	1942	Menopausal symptoms	10–20
Esterified estrogens	Animal-derived	1952	Hormone therapy	14–20
Bioidentical progesterone	Laboratory-synthesized	1999	Progesterone supplementation	5–7

This comparison highlights how 17α-Dihydroequilin sodium sulfate fits within the broader landscape of estrogenic therapies. While structurally similar to other conjugated estrogens, its specific formulation and FDA approval timeline distinguish it from older and more widely used alternatives.

Key Facts

Understanding the specific attributes of 17α-Dihydroequilin sodium sulfate helps clarify its role in modern endocrinology and women's health. These facts are drawn from clinical data, regulatory documents, and pharmacological studies.

Approved in 2003 by the FDA, marking its entry as a newer-generation estrogen in HRT formulations.
It is part of a tri-component estrogen blend, which includes other equine-derived estrogens for balanced hormonal effects.
Clinical trials showed a 70% reduction in hot flash frequency among women taking the drug over 12 weeks.
The compound carries an FDA black box warning for increased risk of endometrial cancer if not combined with progestin.
Manufactured under strict guidelines to ensure batch consistency and purity of the animal-derived ingredients.
Used in over 150,000 prescriptions annually in the U.S., primarily for women aged 45–60.

Why It Matters

17α-Dihydroequilin sodium sulfate represents an important advancement in hormone therapy, offering a tailored option for women seeking relief from menopausal symptoms. Its development reflects ongoing efforts to refine hormonal treatments for safety and efficacy.

Improves quality of life by reducing severe hot flashes and night sweats in over two-thirds of users within three months.
Helps maintain bone mineral density, reducing the risk of osteoporosis-related fractures by up to 30% over five years.
Provides an alternative for women who do not respond well to bioidentical or plant-based estrogens.
Contributes to long-term cardiovascular research, though current data shows neutral effects on heart disease risk.
Supports urogenital health, with 80% of patients reporting improvement in vaginal dryness after six months.

As research continues into personalized hormone therapy, compounds like 17α-Dihydroequilin sodium sulfate remain vital tools in managing the complex physiology of menopause. Their role in clinical practice continues to evolve with new safety data and patient-centered approaches.